Bradley Foster & Sargent Inc. CT Has $58.24 Million Stake in IDEXX Laboratories, Inc. $IDXX

Bradley Foster & Sargent Inc. CT trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.0% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 103,654 shares of the company’s stock after selling 1,039 shares during the period. Bradley Foster & Sargent Inc. CT owned 0.13% of IDEXX Laboratories worth $58,242,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDXX. Empowered Funds LLC raised its position in shares of IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after purchasing an additional 95 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of IDEXX Laboratories during the 2nd quarter worth $265,000. Jump Financial LLC boosted its holdings in shares of IDEXX Laboratories by 1,006.4% during the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after buying an additional 5,032 shares during the period. Cary Street Partners Financial LLC acquired a new position in IDEXX Laboratories in the 2nd quarter valued at $164,000. Finally, Sei Investments Co. grew its stake in IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after buying an additional 82,755 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Up 0.9%

Shares of IDXX stock opened at $544.32 on Friday. The firm has a market capitalization of $42.94 billion, a P/E ratio of 40.08, a price-to-earnings-growth ratio of 2.98 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The firm’s fifty day simple moving average is $556.27 and its 200 day simple moving average is $595.41. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the prior year, the firm earned $2.91 EPS. The business’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group decreased their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Citigroup started coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price objective on the stock. Finally, Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.